6HN 주식 개요 에버레스트 메디신스는 중화권 및 기타 아시아 태평양 시장에서 충족되지 않은 중요한 의료 수요를 해결하기 위해 치료제와 백신의 발견, 라이선스 인, 개발 및 상용화에 관여하는 바이오 제약 회사입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Everest Medicines Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Everest Medicines 과거 주가 현재 주가 HK$4.84 52주 최고치 HK$6.00 52주 최저치 HK$1.65 베타 1.82 1개월 변경 -12.00% 3개월 변경 사항 41.52% 1년 변경 사항 144.44% 3년 변화 45.78% 5년 변화 n/a IPO 이후 변화 -53.01%
최근 뉴스 및 업데이트
Everest Medicines Announces First Prescription of VELSIPITY in Greater Bay Area, Officially Benefiting Mainland China Patients Dec 18
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis Dec 17
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients Dec 12
Everest Medicines Announces Acceptance of Velsipity New Drug Application in Hong Kong Dec 02
Everest Medicines Announces Nefecon, the World's First Approved Treatment for IGA Nephropathy, Is Included in China's National Reimbursement Drug List Nov 28
Everest Medicines Announces Two In Vitro Studies on Eravacycline (XERAVA) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity Nov 22 더 많은 업데이트 보기
Everest Medicines Announces First Prescription of VELSIPITY in Greater Bay Area, Officially Benefiting Mainland China Patients Dec 18
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis Dec 17
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients Dec 12
Everest Medicines Announces Acceptance of Velsipity New Drug Application in Hong Kong Dec 02
Everest Medicines Announces Nefecon, the World's First Approved Treatment for IGA Nephropathy, Is Included in China's National Reimbursement Drug List Nov 28
Everest Medicines Announces Two In Vitro Studies on Eravacycline (XERAVA) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity Nov 22
Everest Medicines Announces NEFECON Receives Full Approval from South Korea's Ministry of Food and Drug Safety for the Treatment of Primary IgA Nephropathy Nov 19
Everest Medicines Limited Announces Business Update on NEFECON Development Oct 24
Now 21% undervalued Oct 03
First half 2024 earnings released Sep 02
No longer forecast to breakeven Aug 28
New minor risk - Profitability Aug 28
Everest Medicines Limited to Report First Half, 2024 Results on Aug 27, 2024 Aug 05
Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis Jul 22
Now 21% undervalued after recent price drop Jul 19
Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration Jul 18
Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis Jul 15
Everest Medicines Limited, Annual General Meeting, Jun 28, 2024 Jun 06
Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China May 15
Now 22% overvalued after recent price rise May 10
Everest Medicines Announces New Drug Application Approval of Velsipity® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau May 08
Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients May 02
Full year 2023 earnings released Mar 30
Forecast to breakeven in 2026 Mar 28
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer Mar 19
Now 23% overvalued after recent price rise Mar 18
Everest Medicines Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 06
Everest Medicines Limited Announces Board Changes Feb 09
Now 22% undervalued after recent price drop Jan 30
Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023 Jan 22
Everest Medicines Limited Announces Directorate Changes Jan 12
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients Dec 27 Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024 Nov 29
Calliditas’ Partner Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy Nov 27
National Medical Products Administration Approves the New Drug Application for Nefecon for the Treatment of Primary Immunoglobulin A Nephropathy in Adults At Risk of Disease Progress in China Nov 25
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy Oct 27
Everest Medicines Limited Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients Sep 28
New major risk - Revenue and earnings growth Aug 28
First half 2023 earnings released: CN¥1.40 loss per share (vs CN¥2.26 loss in 1H 2022) Aug 27
Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon(R) for the Treatment of Primary IgA Nephropathy Aug 25
Everest Medicines Limited to Report First Half, 2023 Results on Aug 24, 2023 Aug 09
Everest Medicines Announces Completion of Patient Enrollment in Nefecon®? China Open Label Extension Study Aug 02
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA in China Jul 27
Everest Medicines Appoints Mike Berry as Chief Technology Officer Jun 16
Everest Medicines Limited, Annual General Meeting, Jun 29, 2023 May 31
Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia May 17
No longer forecast to breakeven Apr 03
Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary Iga Nephropathy Feb 10
Everest Medicines Limited Announces Board Changes Jan 20 Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China Jan 18
Everest Medicines Aims to Initiate Clinical Trials and File an Emergency Use Authorization Application in 2023 in China for Its Lead mRNA Candidate Jan 04 Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone Dec 15
Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy Nov 28
Less than half of directors are independent Nov 16
Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy Nov 15
Everest Medicines Announces Approval of XERAVA in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections Oct 08
Forecast to breakeven in 2022 Sep 27
Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001 Sep 26 Everest Medicines Appoints Rogers Yongqing Luo as an Executive Director Everest Medicines Limited Announces Resignation of Kerry Blanchard as A Member of the Board of Directors
Everest Medicines Limited to Report First Half, 2022 Results on Aug 24, 2022 Aug 13
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan Aug 11
Everest Medicines Announces Approval of Trodelvy in China for Second-Line Metastatic Triple-Negative Breast Cancer Jun 10
Less than half of directors are independent Apr 27
Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis Apr 06 Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan
Forecast to breakeven in 2024 Mar 30
Everest Medicines Limited, Annual General Meeting, Jun 30, 2022 Mar 30
Everest Medicines Limited Appoints Leah Liu as Joint Company Secretary Mar 29
Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer Feb 07
Everest Medicines Limited Announces Resignation of Ms. Yin Yin as Joint Company Secretary Feb 01
Everest Medicines Will Participate in Clinical Trial with Gilead and Msd to Evaluate Trodelvy® in Combination with Keytruda® (Pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer Jan 12
Everest Medicines Limited Announces Taiwan FDA Has Accepts New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer Jan 04
Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program Dec 21
Everest Medicines Limited Announces Acceptance of New Drug Application for Sacituzumab Govitecan Dec 15
Everest Medicines Limited Receives Approval for Investigational New Drug Application for SPR206 from National Medical Products Administration Sep 25
Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer Aug 27
Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia Aug 06
Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer May 21
Everest Medicines announces that the China National Medical Products Administration has accepted for review its Biologics License Application for sacituzumab govitecan-hziy May 18
Everest Medicines Limited Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer May 07
Everest Medicines Limited to Report Fiscal Year 2020 Results on Mar 21, 2021 Mar 11 주주 수익률 6HN DE Biotechs DE 마켓 7D 0.8% -2.1% 3.0% 1Y 144.4% -3.8% 12.8%
전체 주주 수익률 보기
수익률 대 산업: 6HN 지난 1년 동안 -3.8 %를 반환한 German Biotechs 산업을 초과했습니다.
수익률 대 시장: 6HN 지난 1년 동안 12.8 %를 반환한 German 시장을 초과했습니다.
가격 변동성 Is 6HN's price volatile compared to industry and market? 6HN volatility 6HN Average Weekly Movement 12.6% Biotechs Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: 6HN 의 주가는 지난 3개월 동안 German 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: 6HN 의 주간 변동성 ( 13% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 에버레스트 메디신스는 중화권 및 기타 아시아 태평양 시장에서 충족되지 않은 중요한 의료 수요를 해결하기 위해 치료제와 백신의 발견, 라이선스 인, 개발 및 상용화에 관여하는 바이오 제약 회사입니다. 이 회사의 파이프라인에는 면역글로불린 신증(IgAN) 치료를 위한 경구용 부데소니드 제제인 네페콘, 감수성 그람 양성, 그람 음성 및 혐기성 병원체에 의한 감염 치료를 위한 완전 합성 플루오로사이클린 정맥 항생제인 제라바 등이 있습니다; 중증 세균 감염 환자 치료를 위해 임상 3상 시험 중인 베타 락타마제 억제제(BLI)인 타니보르박탐, 중등도에서 중증의 활성 궤양성 대장염 치료를 위해 임상 3상 시험 중인 경구 선택적 스핑고신 1-포스페이트(S1P) 수용체 조절제인 에트라시모드(Etrasimod). 루푸스 신염을 포함한 다양한 면역 매개 질환을 대상으로 임상 2b상 중인 면역 프로테아좀 억제제인 제토밉조밉, 신장 질환 치료를 위해 임상 1b상 중인 공유 가역적 브루톤 티로신 키나제(BTK) 억제제인 EVER001, 암 및 자가 면역 질환을 위한 mRNA 플랫폼 치료 백신을 공급하고 있습니다.
자세히 보기 Everest Medicines Limited 기본 사항 요약 Everest Medicines 의 수익과 매출은 시가총액과 어떻게 비교하나요? 6HN 기본 통계 시가총액 €1.56b 수익(TTM ) -€139.91m 수익(TTM ) €55.60m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 6HN 손익 계산서(TTM ) 수익 CN¥418.55m 수익 비용 CN¥101.53m 총 이익 CN¥317.02m 기타 비용 CN¥1.37b 수익 -CN¥1.05b
주당 순이익(EPS) -3.27 총 마진 75.74% 순이익 마진 -251.64% 부채/자본 비율 10.9%
6HN 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/20 14:27 장 마감 주가 2025/01/17 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Everest Medicines Limited 13 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Bo Li BofA Global Research Ziyu He China International Capital Corporation Limited Jin Zhang China International Capital Corporation Limited
10 더 많은 분석가 보기 
